2. Search Result
Search Result
Results for "

inflammatory dermatitis

" in MedChemExpress (MCE) Product Catalog:

111

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dyes

1

Biochemical Assay Reagents

5

Peptides

17

Inhibitory Antibodies

15

Natural
Products

10

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0184A
    Dipotassium glycyrrhizinate
    Maximum Cited Publications
    59 Publications Verification

    Glycyrrhizic acid dipotassium; Dipotassium glycyrrhizate

    		 Virus Protease Metabolic Disease Inflammation/Immunology
    Dipotassium glycyrrhizinate is a HMGB1 inhibitor, inhibits atopic dermatitis-related gene expression with anti-anti-inflammatory activity .
    Dipotassium glycyrrhizinate
  • HY-B0636
    Triamcinolone acetonide
    5+ Cited Publications

    		 Glucocorticoid Receptor FGFR Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Triamcinolone acetonide inhibits basic fibroblast growth factor (bFGF) induced proliferation of retinal endothelial cells. Triamcinolone acetonide reduces chondrocyte viability and leads to cartilage destruction. Triamcinolone acetonide activates macrophage with anti-inflammatory characteristics. Triamcinolone acetonide can be used in the study of diseases such as atopic dermatitis .
    Triamcinolone acetonide
  • HY-13516
    Aloperine
    5+ Cited Publications

    		 Apoptosis Autophagy Filovirus HIV Infection Inflammation/Immunology Cancer
    Aloperine is an alkaloid in sophora plants such as Sophora alopecuroides L, which has shown anti-cancer, anti-inflammatory and anti-virus properties . Aloperine is widely used to treat patients with allergic contact dermatitis eczema and other skin inflammation in China . Aloperine induces apoptosis and autophagy in HL-60 cells .
    Aloperine
  • HY-P99025
    Lebrikizumab
    1 Publications Verification

    TNX-650; MILR1444A; RG3637

    		 Interleukin Related Neurological Disease Inflammation/Immunology
    Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases .
    Lebrikizumab
  • HY-148074
    Zelnecirnon

    RPT193

    		 CCR Inflammation/Immunology
    Zelnecirnon (RPT193) is an orally active inhibitor of CCR4, blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. Zelnecirnon can be used for allergic inflammation in atopic dermatitis, asthma, and other diseases research .
    Zelnecirnon
  • HY-103018
    Gusacitinib
    1 Publications Verification

    ASN-002

    		 JAK Syk Inflammation/Immunology Cancer
    Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
    Gusacitinib
  • HY-76711
    Naltrexone

    		Opioid Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight .
    Naltrexone
  • HY-145551
    Atinvicitinib

    		JAK Interleukin Related Inflammation/Immunology
    Atinvicitinib is an orally active and selective JAK1 inhibitor. Atinvicitinib blocks signaling of JAK1-dependent pruritogenic and pro-inflammatory cytokines, including those in the IL-31, IL-4, and IL-13 pathways. Atinvicitinib can be used for the researches of pruritus associated with allergic dermatitis and canine atopic dermatitis .
    Atinvicitinib
  • HY-13723
    Pimecrolimus
    4 Publications Verification

    SDZ-ASM 981

    		 Phosphatase Inflammation/Immunology
    Pimecrolimus (SDZ-ASM 981) is a potent, nonsteroid and orally active calcineurin inhibitor with a Ki of 117 nM. Pimecrolimus shows anti-inflammatory activity .
    Pimecrolimus
  • HY-P99519
    Vixarelimab
    1 Publications Verification

    KPL-716

    		 Interleukin Related Inflammation/Immunology
    Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
    Vixarelimab
  • HY-B0248
    Desonide
    2 Publications Verification

    		 Glucocorticoid Receptor Huntingtin Apoptosis Neurological Disease Inflammation/Immunology
    Desonide is a non-fluorinated corticosteroid anti-inflammatory agent that acts on the glucocorticoid receptor. Desonide can also specifically bind to the mutant huntingtin protein (mHTT), reducing the level and toxicity of mHTT. Desonide can be used in the research of Huntington's disease and inflammatory diseases such as atopic dermatitis .
    Desonide
  • HY-B0328
    Triamcinolone
    2 Publications Verification

    		 Glucocorticoid Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Triamcinolone is a long-acting corticosteroid with anti-inflammatory, anti-oedematous, anti-proliferative, anti-angiogenetic, immunomodulatory and neuroprotective effects through binding to glucocorticoid receptors. Triamcinolone can relieve several dermatitis, immune diseases and ocular diseases .
    Triamcinolone
  • HY-P991162
    Tilrekimig

    PF-07275315

    		 Interleukin Related Inflammation/Immunology
    Tilrekimig (PF-07275315) is a monoclonal antibody targeting human interleukin-4 (IL-4), interleukin-13 (IL-13) and thymic stromal lymphopoietin (TSLP). Tilrekimig can be used in the research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
    Tilrekimig
  • HY-163731
    EGR-1-IN-1
    2 Publications Verification

    		 DNA Methyltransferase Interleukin Related Inflammation/Immunology
    EGR-1-IN-1 is a EGR-1 inhibitor with an IC50 of 1.86 μM. EGR-1-IN-1 binds to the zinc finger DNA-binding domain of EGR-1 and promotes the dissociation of the EGR-1-DNA complex. EGR-1-IN-1 reduces the mRNA expression levels of EGR-1-regulated inflammatory genes induced by TNFα. EGR-1-IN-1 alleviates atopic dermatitis-like lesions in the ear skin of mice. EGR-1-IN-1 serves as a lead compound for the development of targeted compounds for inflammatory skin diseases. EGR-1-IN-1 can be used in studies related to atopic dermatitis .
    EGR-1-IN-1
  • HY-P99555
    Tomaralimab

    OPN-305

    		 Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
    Tomaralimab
  • HY-W010520
    Methylisothiazolinone

    		Environmental Pollutants MMP Bacterial Fungal Apoptosis Infection Inflammation/Immunology
    Methylothiazolinone is a bacterial and fungal inhibitor and preservative, as well as a sensitizer. Methylisothiazolinone can activate matrix metalloproteinases (MMPs) in human bronchial epithelial cells to induce apoptosis and inflammatory response. Methylisothiazolinone can promote the development of atopic dermatitis in mice by disrupting Th2/Th17 related immune responses. Methylisothiazolinone can cause mitochondrial damage in the endothelium of rat cerebral blood vessels .
    Methylisothiazolinone
  • HY-158399
    STAT6-IN-5

    		STAT Inflammation/Immunology
    STAT6-IN-5 (compound 84) is a STAT6 inhibitor (IC50=0.24 μM), which can be used for the research of inflammatory diseases and allergic diseases (e.g. atopic dermatitis) .
    STAT6-IN-5
  • HY-N0184AR
    Dipotassium glycyrrhizinate (Standard)

    Glycyrrhizic acid dipotassium (Standard); Dipotassium glycyrrhizate (Standard)

    		 Reference Standards Virus Protease Metabolic Disease Inflammation/Immunology
    Dipotassium glycyrrhizinate (Standard) is the analytical standard of Dipotassium glycyrrhizinate. This product is intended for research and analytical applications. Dipotassium glycyrrhizinate is a HMGB1 inhibitor, inhibits atopic dermatitis-related gene expression with anti-anti-inflammatory activity .
    Dipotassium glycyrrhizinate (Standard)
  • HY-111940
    LUT014

    		Raf p38 MAPK ERK Inflammation/Immunology
    LUT014 is a topical inhibitor targeting BRAF that cannot pass through the blood-brain barrier. LUT014 inhibits BRAF kinase and abnormally activates the MAPK/ERK signaling pathway, promoting the proliferation of epidermal keratinocytes, repairing skin barrier damage caused by radiation damage, and alleviating inflammatory responses. LUT014 is independent of RAS signaling and accelerates the repair and regeneration of damaged skin cells. LUT014 can be used to study radiation dermatitis, especially skin damage caused by breast cancer radiotherapy .
    LUT014
  • HY-B1616
    Clobetasone butyrate
    1 Publications Verification

    		 Glucocorticoid Receptor Inflammation/Immunology
    Clobetasone butyrate is a synthetic glucocorticoid and has topical anti-inflammatory activity especially in skin. Clobetasone butyrate can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis .
    Clobetasone butyrate
  • HY-100009
    Ufenamate

    Flufenamic acid butyl ester; Butyl flufenamate

    		 COX Prostaglandin Receptor Inflammation/Immunology
    Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug that can be used in the study of skin diseases such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliary rashes and atopic dermatitis. Ufenamate has a certain photoprotective effect, reduces the degree of skin erythema and swelling in the photoaging model, downregulates the expression level of COX-2 and can promote the healing of mouse skull defects by secreting BMP2 .
    Ufenamate
  • HY-A0158
    Diflorasone
    2 Publications Verification

    		 Glucocorticoid Receptor Cardiovascular Disease Inflammation/Immunology
    Diflorasone is a potent topical anti-inflammatory Corticosteroid. Diflorasone induces vasoconstriction when applied topically. Diflorasone can be used in research related to psoriasis, atopic dermatitis/neurodermatitis .
    Diflorasone
  • HY-W041608
    Methylchloroisothiazolinone

    		NF-κB Toll-like Receptor (TLR) Bacterial Infection Inflammation/Immunology
    Methylchloroisothiazolinone is a widely used fungicide and also an aquatic pollutant with pro-inflammatory activity and neurotoxicity. Methylchloroisothiazolinone induces the production of pro-inflammatory cytokines (such as IL-1β, TNF-α, IL-6) by activating the NF-κB signaling pathway and upregulating TLR4 expression, thereby triggering allergic contact dermatitis. Methylchloroisothiazolinone reduces cholinesterase activity and exacerbates oxidative stress by impairing catalase activity and disrupting redox balance. Methylchloroisothiazolinone poses significant harm to Mediterranean mussels, reducing the viability of hemocytes and digestive gland cells, inhibiting immune phagocytic function, and disrupting osmoregulatory capacity. Methylchloroisothiazolinone is used in studies on allergic contact dermatitis and related immunotoxicity mechanisms .
    Methylchloroisothiazolinone
  • HY-P990906
    Bosakitug

    BSI-045B; TQC2731

    		 Interleukin Related Inflammation/Immunology
    Bosakitug (BSI-045B) is an TSLP-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Bosakitug can be used in the research of inflammatory diseases such as moderate to severe atopic dermatitis .
    Bosakitug
  • HY-40020
    1-Boc-3-piperidone

    		Biochemical Assay Reagents Drug Intermediate Inflammation/Immunology Cancer
    1-Boc-3-piperidone is a Boc-protected piperidone derivative. 1-Boc-3-piperidone is an important intermediate in organic synthesis. 1-Boc-3-piperidone can be used to study compounds related to inflammatory skin diseases (such as atopic dermatitis), lymphoma, and other diseases .
    1-Boc-3-piperidone
  • HY-B0426A
    Olopatadine hydrochloride

    ALO4943A; KW4679

    		 Histamine Receptor CXCR Infection Neurological Disease Metabolic Disease Inflammation/Immunology
    Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine hydrochloride
  • HY-P991598
    MOR-106

    MOR12743; MOR03207

    		 Interleukin Related NF-κB Inflammation/Immunology
    MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
    MOR-106
  • HY-P5255
    Oligopeptide-10

    		Bacterial Infection Inflammation/Immunology
    Oligopeptide-10 is a bioactive peptide with antimicrobial activity. Oligopeptide-10 exhibits broad-spectrum bactericidal effects against Gram-positive bacteria including Propionibacterium acnes and Staphylococcus aureus. Oligopeptide-10 targets lipoteichoic acid (LTA) on the surface of bacterial cell membranes, induces bacterial osmotic imbalance by disrupting the integrity of bacterial membranes, and reduces the release of pro-inflammatory cytokines induced by bacteria. Oligopeptide-10 possesses skin-protective activity. Oligopeptide-10 can be applied in research related to acne vulgaris, dandruff, seborrheic dermatitis, and tinea pedis .
    Oligopeptide-10
  • HY-B1365
    Prednicarbate

    		Glucocorticoid Receptor Inflammation/Immunology
    Prednicarbate is a topical corticosteroid agent. Prednicarbate can be used for the research of inflammatory skin diseases, such as atopic dermatitis .
    Prednicarbate
  • HY-P990016
    Temtokibart

    ARGX-112; LEO-138559; LP-0145

    		 Interleukin Related Inflammation/Immunology
    Temtokibart (ARGX-112) is a monoclonal antibody and also an IL-22RA1 inhibitor. Temtokibart inhibits the signal transduction of IL-22, IL-20 and IL-24. Temtokibart reduces the expression levels of inflammatory proteins, chemokines, immune cell migration and markers of activated immune pathways. Temtokibart improves the expression of genes related to immunity and epidermal barrier function. Temtokibart is applicable to research on moderate-to-severe atopic dermatitis .
    Temtokibart
  • HY-114354
    BODIPY FL alkyne

    BOD FL alkyne

    		 Fluorescent Dye Inflammation/Immunology
    BODIPY (BOD) FL alkyne is an alkyne-containing BODIPY fluorophore derivative. BODIPY FL alkyne is a bioorthogonal labeling reagent with low toxicity and extremely low non-specific reactivity, and it is widely used in fluorescent bioimaging. BODIPY FL alkyne specifically labels azide groups on intracellular glycoconjugates mainly via strain-promoted azide-alkyne cycloaddition (SPAAC), or mediates site-specific conjugation with proteins such as IL-33, and supports positive cross-linking with other probes (e.g., DBCO-SCy5) for dual labeling. With the advantages of high specificity and low background interference, BODIPY FL alkyne can be used in the research of related diseases such as asthma, atopic dermatitis and inflammatory bowel disease .
    BODIPY FL alkyne
  • HY-17570
    Desoximetasone
    1 Publications Verification

    		 Glucocorticoid Receptor Interleukin Related Cytochrome P450 Inflammation/Immunology
    Desoximetasone is a corticosteroid and a substrate of cytochrome P450 3A4. Desoximetasone has anti-inflammatory, anti-allergic, and immunosuppressive effects. Desoximetasone can be used in the research of various skin diseases, such as skin allergies, atopic dermatitis, and psoriasis .
    Desoximetasone
  • HY-W010243
    Methylisothiazolinone hydrochloride

    		Bacterial MMP Apoptosis Fungal Infection Inflammation/Immunology
    Methylisothiazolinone hydrochloride is a bacterial and fungal inhibitor and preservative, as well as a sensitizer. Methylisothiazolinone hydrochloride can activate matrix metalloproteinases (MMPs) in human bronchial epithelial cells to induce apoptosis and inflammatory response. Methylisothiazolinone hydrochloride can promote the development of atopic dermatitis in mice by disrupting Th2/Th17 related immune responses. Methylisothiazolinone hydrochloride can cause mitochondrial damage in the endothelium of rat cerebral blood vessels .
    Methylisothiazolinone hydrochloride
  • HY-N3312
    Matairesinol

    		p38 MAPK JNK NF-κB Metabolic Disease Inflammation/Immunology Cancer
    Matairesinol is an orally active bioactive compound with anti-inflammatory, antioxidant and anticancer activities. Matairesinol inhibits the phosphorylation of MAPK, JNK and NF-κB, downregulates RANKL-induced NFATc1 expression and activity, and suppresses the activation of the PI3K/AKT/FOXO1 pathway. Matairesinol can be used in research related to sepsis-mediated brain injury, osteoporosis, heart failure, atopic dermatitis and cancer .
    Matairesinol
  • HY-N8593
    Undecane

    		Environmental Pollutants p38 MAPK TNF Receptor NF-κB Interleukin Related Histamine Receptor PKA Inflammation/Immunology Endocrinology
    Undecane is a potent cAMP agonist with anti-allergic and anti-inflammatory activities. Undecane inhibits degranulation and the secretion of histamine and TNF-α. Undecane reverses the increased levels of p38 phosphorylation, NF-κB transcriptional activity and target cytokine/chemokine genes, including thymus and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC) and interleukin-8 (IL-8). Undecane can be used for the study of skin inflammatory disorders, such as atopic dermatitis .
    Undecane
  • HY-156622
    Leramistat

    HMC-C-01-A; MBS2320

    		 Mitochondrial Metabolism Cancer
    Leramistat (HMC-C-01-A; MBS2320) is a mitochondrial complex 1 inhibitor, involving in cell metabolism immune metabolism regulation. Leramistat also inhibits ATP production in Thp1 human monocytes (IC50: 0.63 μM). Leramistat inhibits atopic dermatitis and other skin diseases autoimmune diseases, inflammatory diseases, cancer; and also inhibits osteoclast mediated disease .
    Leramistat
  • HY-W062109
    Olopatadine

    		Histamine Receptor CXCR Inflammation/Immunology
    Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine
  • HY-76711S
    Naltrexone-d4

    		Isotope-Labeled Compounds Opioid Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Naltrexone-d4 is deuterium labeled Naltrexone (HY-76711). Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.
    Naltrexone-d4
  • HY-156621
    Lepzacitinib

    		JAK Inflammation/Immunology
    Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases .
    Lepzacitinib
  • HY-116691
    Hydrocortisone aceponate

    Hydrocortisone 17-propionate 21-acetate

    		 Glucocorticoid Receptor Neurological Disease Inflammation/Immunology
    Hydrocortisone aceponate (Hydrocortisone 17-propionate 21-acetate) is a diester-based topical glucocorticoid. Hydrocortisone aceponate alleviates symptoms such as erythema, dryness/desquamation, pruritus, epidermal exfoliation, and exudation/crusting. Hydrocortisone aceponate causes extremely few adverse reactions. Hydrocortisone aceponate is applicable to various dermatological disease studies .
    Hydrocortisone aceponate
  • HY-P1722
    Spantide II
    1 Publications Verification

    		 Neurokinin Receptor Inflammation/Immunology
    Spantide II, an undecapeptide substance P (SP) analog, is a potent neurokinin-1 receptor (NK-1R) antagonist. Spantide II binds with NK-1R and blocks proinflammatory activities associated with SP. Spantide II can be used in the research of inflammatory skin disorders, such as psoriasis and contact dermatitis .
    Spantide II
  • HY-156959
    Ovalicin

    		JAK TRP Channel MetAP Infection Inflammation/Immunology
    Ovalicin is a multi-target inhibitor that targets MetAP2, HRH2, JAK2 and TRPV1, with anti-inflammatory and anti-atopic dermatitis activities. Ovalicin covalently binds to MetAP2 to inhibit its function, thereby blocking the replication of Enterocytozoon bieneusi and Vittaforma corneae. Ovalicin alleviates intestinal injury and prolongs survival in infected mouse models, without showing obvious hepatorenal toxicity. Ovalicin attenuates LPS-induced calcium influx, reduces the infiltration of macrophages and mast cells in the skin, and regulates the expression of inflammation-related genes such as IL-31, effectively relieving allergic symptoms in mouse models. Ovalicin can be used for the research of microsporidiosis and atopic dermatitis .
    Ovalicin
  • HY-151876
    Glucocorticoid receptor modulator 1

    		Glucocorticoid Receptor NF-κB AP-1 Inflammation/Immunology
    Glucocorticoid receptor modulator 1 is a highly potent and orally active non-steroidal selective glucocorticoid receptor modulator with an IC50 value of 9 nM and 130 nM for NF-κB and AP-1, respectively. Glucocorticoid receptor modulator 1 can effectively reduce the expression of inflammatory factors IL-6, IL-1β, TNF-α, also can relieve dermatitis in mice .
    Glucocorticoid receptor modulator 1
  • HY-W010243S
    Methylisothiazolinone-d3 hydrochloride

    		Isotope-Labeled Compounds Bacterial MMP Apoptosis Fungal Infection Inflammation/Immunology
    Methylisothiazolinone-d3 hydrochloride is the deuterium labeled Methylisothiazolinone hydrochloride (HY-W010243). Methylisothiazolinone hydrochloride is a bacterial and fungal inhibitor and preservative, as well as a sensitizer. Methylisothiazolinone hydrochloride can activate matrix metalloproteinases (MMPs) in human bronchial epithelial cells to induce apoptosis and inflammatory response. Methylisothiazolinone hydrochloride can promote the development of atopic dermatitis in mice by disrupting Th2/Th17 related immune responses. Methylisothiazolinone hydrochloride can cause mitochondrial damage in the endothelium of rat cerebral blood vessels .
    Methylisothiazolinone-d3 hydrochloride
  • HY-155830
    Morcamilast

    ME3183; PDE4-IN-14

    		 Phosphodiesterase (PDE) Interleukin Related Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Morcamilast (ME3183) is a selective and orally active PDE4 inhibitor, with IC50s of 1.28 nM (PDE4A1A), 2.33 nM (PDE4B1), and 1.63 nM (PDE4D2) respectively. Morcamilast shows weak inhibition of PDEs other than PDE4s Morcamilast is an anti-inflammatory agent and inhibits LPS (HY-D1056)-induced release of TNF-α, IL-12/23p40, IL-23, and IL-17A in human PBMCs and T cells. Morcamilast has antipruritic effect and can be used in the study of psoriasis, atopic dermatitis, and other inflammatory diseases .
    Morcamilast
  • HY-107949
    Flumethasone pivalate

    Flumethasone 21-pivalate

    		 Glucocorticoid Receptor Cardiovascular Disease Inflammation/Immunology
    Flumethasone pivalate (Flumethasone 21-pivalate) is a glucocorticoid and a topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Flumethasone pivalate inhibits foreign body granuloma formation. Flumethasone pivalate can be used for the researches of dermatitis, eczema, and psoriasis .
    Flumethasone pivalate
  • HY-76711R
    Naltrexone (Standard)

    		Reference Standards Opioid Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Naltrexone (Standard) is the analytical standard of Naltrexone (HY-76711). This product is intended for research and analytical applications. Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.
    Naltrexone (Standard)
  • HY-P991150
    Ompekimig

    		Interleukin Related Inflammation/Immunology
    Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
    Ompekimig
  • HY-P991258
    CNTO-5825

    		Interleukin Related Inflammation/Immunology
    CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
    CNTO-5825
  • HY-W1113770
    STAT6-IN-8

    		STAT Inflammation/Immunology
    STAT6-IN-8 is a STAT6 inhibitor with an IC50 of 0.45 μmol/L. STAT6-IN-8 exhibits potential anti-inflammatory and anti-allergic effects. STAT6-IN-8 can be used for the research of atopic dermatitis .
    STAT6-IN-8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: